RISING health care costs could lead to tighter government price controls, a Fitch Group unit said, creating headwinds for pharmaceutical companies and speeding up a shift toward cheaper generics. “The ...

Dublin, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The "International Directory of Generics Companies" directory has been added to ResearchAndMarkets.com's offering. This powerful directory is your connection ...

Credit: Getty Images Aging exerts detrimental physiologic, histologic, and functional effects on the endometrial extracellular matrix and on oocyte quality, impairing conception and implantation. With ...

Sales of weight loss medicines like Ozempic and Mounjaro have skyrocketed in South Africa in recent years. However, they remain too expensive for most people who might benefit from the jabs. Spotlight ...

After a decade of Lupin recovering in the corporate equivalent of an ICU, DBG (Desh Bandhu Gupta) did not mistake the consolation of having avoided disaster for good fortune. The decade since 1993 had ...

Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached its second release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...

Oral anti-obesity formulations will be the next growth lever in Danish drugmaker Novo Nordisk's India strategy, following the 2025 launches of its blockbuster diabetes and obesity brands Ozempic and ...

Lupin Ltd. posted a 37.4 per cent year-on-year (YoY) jump in quarterly net profit to Rs. 1,180.5 crore in Q3 FY26, driven primarily by record US sales, stronger gross margins, and a favourable product ...

Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what’s been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but ...